Universal screening and drug treatment of dyslipidemia in children and adolescents

JAMA

Volumn 307, Issue 3, 2012, Pages 257-258

  Psaty, Bruce M ^a,b,c   Rivara, Frederick P ^a,b,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFIBRATE; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TORCETRAPIB;

ADOLESCENT; CHILD; CHILD CARE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; SHORT SURVEY; TREATMENT INDICATION; TREATMENT RESPONSE; ADULT; ALGORITHM; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); MASS SCREENING; STANDARD;

ADOLESCENT; ALGORITHMS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; YOUNG ADULT;

EID: 84855987839     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1916     Document Type: Short Survey

References (10)

1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
2. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
3. Oliver MF, Heady JA, Morris JN, Cooper J; Report of the Committee of Principal Investigators.WHOcooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;2(8403):600-604. (Pubitemid 14038716)
4. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113- 2122.
5. Trilipix (fenofibric acid): drug safety communication: label change. US Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/ SafetyInformation /SafetyAlertsforHumanMedicalProducts/ucm279185.htm. Accessed November 9, 2011.
6. Barter PJ, Caulfield M, Eriksson M, et al ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-2122. (Pubitemid 350146106)
7. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50(5):409-418. (Pubitemid 47096680)
8. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. (Pubitemid 39577514)
9. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896-1904.
10. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365(20):1876- 1885.